Devil in the Details: An Expert Guide to Modern Multiple Sclerosis Practices (Credit Expired)
This activity is designed to highlight the differences in self-reported diagnostic and therapeutic strategies of MS specialists and general neurologists. With the help of Drs Andrew Solomon, Robert Bermel, and Jiwon Oh, Efficient, ACTRIMS, and Postgraduate Institute for Medicine conducted a case-based survey of 26 MS Experts and 100 community-based neurologists to evaluate a variety of different MS scenarios such as their competency with the McDonald criteria and use of new agents. Throughout the program, experts will provide commentary on select survey results, with a focus on areas of heterogeneity, as well as illustrate their own approaches to these issues in their clinical practice.
General neurologists, multiple sclerosis (MS) specialists, nurse practitioners, physician assistants, and other healthcare professionals involved in the care of patients with MS.
Upon completion of this activity, participants will be able to:
- Identify the most commonly misunderstood or misapplied core components of the McDonald criteria and recognize the appropriate way to apply these concepts in order to arrive at a timely and accurate MS diagnosis.
- Assess the merits and uses of both qualitative and quantitative disability assessments in MS to better select the most appropriate and practical tests in clinical practice.
- Appraise key indicators for MS risk stratification to improve strategic decision-making in treatment initiation and subsequent long-term outcomes for patients who present with variable disease activity.
- Evaluate important considerations and factors in DMT switching in order to optimally tailor therapeutic decisions to individual patient needs.
Andrew Solomon, MD (Chair)
Division Chief, Multiple Sclerosis Center
Associate Professor, Larner College of Medicine
University of Vermont
Burlington, Vermont, United States
Robert Bermel, MD (Panelist)
Staff Neurologist and Director
Mellen Center for Multiple Sclerosis
Cleveland, Ohio, United States
Jiwon Oh, MD, PhD, FRCPC (Panelist)
Medical Director, Barlo MS Program
St. Michael’s Hospital
Scientist, Keenan Research Centre
Li Ka Shing Knowledge Institute
Associate Professor of Medicine
University of Toronto
Toronto, Ontario, Canada
Credit for this program has expired. The accreditation information below is based on the activity release date.
Jointly provided by Postgraduate Institute for Medicine, Efficient LLC, and ACTRIMS.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PIM designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC and ACTRIMS planners and managers have nothing to disclose.
Dr. Solomon reported no relevant financial relationships.
Dr. Bermel reported the following financial relationships:
- Advisor or consultant for: Biogen; EMD Serono; Genentech/Roche; Novartis; Sanofi Genzyme; Viela Bio
- Grants for clinical research from: Biogen; Genentech/Roche; Novartis
- Royalties or patent beneficiary: Multiple Sclerosis Performance Test
Dr. Oh reported the following financial relationships:
- Advisor or consultant for: Alexion; Biogen; Bristol Myers Squibb; Novartis; Roche; Sanofi Genzyme
- Grants for clinical research from: Biogen; EMD Serono; Roche
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by educational grants from Biogen, Bristol Myers Squibb, and Genentech.